U-Ploid

U-Ploid specializes in innovative fertility solutions that target age-related infertility, providing advanced treatments to enhance older egg cell quality and improve IVF success rates for women in their mid-30s to 40s. U-Ploid Biotechnologies was founded in 2024 in Oxford, UK. The company focuses on developing treatments that improve egg cell quality for older women undergoing in vitro fertilization (IVF). As of January 7, 2024, U-Ploid has completed one funding round.

The company was founded by individuals with backgrounds in reproductive health, though specific names are not disclosed. U-Ploid Biotechnologies is focused on revolutionizing fertility care through innovative solutions aimed at addressing age-related infertility. The company’s primary offerings include advanced treatments designed to enhance the quality of older egg cells, integrating seamlessly with existing in vitro fertilization (IVF) protocols. These products aim to improve success rates for women in their mid-30s to 40s, a demographic that traditionally experiences decreased fertility outcomes.

The end users of U-Ploid's products primarily consist of women seeking to conceive later in life, as well as fertility clinics and reproductive health providers that serve this population. Geographically, U-Ploid markets its products to clinics and healthcare facilities across North America, Europe, and select regions in Asia, providing a global outreach to address a widespread need for effective fertility solutions. The revenue model for U-Ploid Biotechnologies is structured around partnerships with fertility clinics and healthcare providers, facilitating the integration of their innovative treatments into existing IVF workflows. Revenue is generated through direct sales and potentially through collaborative agreements or licensing arrangements with these healthcare partners.

Each treatment or procedure associated with their flagship offerings is designed to be scalable, allowing clinics to offer these solutions as part of their standard fertility services. The company’s pricing plans are set to reflect the advanced nature of their technologies, ensuring that clients can access effective care while maintaining sustainable operational costs for clinics. By focusing on the quality of their products and the efficacy of treatments, U-Ploid positions itself as a leader in the fertility sector, catering specifically to the needs of women experiencing age-related infertility challenges. In January 2024, U-Ploid raised an undisclosed amount of pre-seed funding from new investor Blue Collective.

The company is planning to expand its product line with new fertility treatments set to launch within the next year, focusing on enhancing support for women experiencing age-related infertility. U-Ploid aims to penetrate new markets in Asia and Europe by 2025, aiming to increase accessibility to their innovative solutions. The recent funding will be utilized to support product development and market entry strategies, ensuring that U-Ploid can effectively address the needs of women in these new regions.